US 12,465,615 B2
Aqueous solutions containing purines and pyrimidines and uses thereof
Paul Glidden, Emeryville, CA (US); and Eric Scharin, Emeryville, CA (US)
Assigned to UCB BIOSCIENCES, INC., Morrisville, NC (US)
Filed by UCB BIOSCIENCES, INC., Morrisville, NC (US)
Filed on Mar. 25, 2022, as Appl. No. 17/705,060.
Claims priority of provisional application 63/166,860, filed on Mar. 26, 2021.
Prior Publication US 2022/0305041 A1, Sep. 29, 2022
Int. Cl. A61K 31/708 (2006.01); A61K 31/7068 (2006.01); A61K 31/7072 (2006.01); A61K 31/7076 (2006.01)
CPC A61K 31/708 (2013.01) [A61K 31/7068 (2013.01); A61K 31/7072 (2013.01); A61K 31/7076 (2013.01)] 34 Claims
 
1. A composition comprising a first heteroaryl compound and a second heteroaryl compound dissolved in an aqueous liquid, wherein the solubility of the first heteroaryl compound in the aqueous liquid is higher by 10 mg/mL or more compared with an otherwise identical aqueous liquid that lacks the second heteroaryl compound, and
wherein the first heteroaryl compound is Compound G

OG Complex Work Unit Chemistry
and the second heteroaryl compound is Compound A,

OG Complex Work Unit Chemistry
or the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine;
wherein if the first heteroaryl compound is Compound G
and the second heteroaryl compound is Compound A,
then a concentration of Compound A is about 30 mg/mL or more and a concentration of Compound G is about 60 mg/mL or more; and
wherein if the first heteroaryl compound is deoxythymidine and the second heteroaryl compound is deoxycytidine, then a concentration of deoxycytidine is about 50 mg/mL or more, and a concentration of deoxythymidine is about 60 mg/mL or more.